Latest News and Press Releases

Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.

Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in 6MWD, cardiac effort and QoL.

Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the full year ended December 31, 2024.

Liquidia has entered into a sixth amendment to its agreement with HealthCare Royalty to provide for up to an additional $100 million of financing.

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Liquidia's Chief Executive Officer, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.

Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024.

Liquidia Corporation (LQDA) to present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET.